Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | NOTUM | Q6P988 | 2/20 | 1.00 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21887193 | 0.84 | NPC1 (0.79) | KDM4ENOTUMNPC1RAB9AHSD17B10 | |
| SCHEMBL26673871 | 0.83 | NPC1 (0.78) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL10112953 | 0.79 | KDM4E (0.66) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL12550898 | 0.79 | KDM4E (0.66) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL20767009 | 0.79 | NPC1 (0.72) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL6903361 | 0.79 | KDM4E (1.00) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL15718167 | 0.79 | DGAT1 (1.00) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL11476623 | 0.79 | KDM4E (0.65) | KDM4ENOTUMNPC1RAB9AHSD17B10 | |
| SCHEMBL10308910 | 0.79 | KDM4E (0.65) | KDM4ENOTUMDGAT1NPC1RAB9A | |
| SCHEMBL28273185 | 0.79 | KDM4E (0.65) | KDM4ENOTUMDGAT1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059901-A | 1,3, 4-Oxadiazole compound and preparation method and application thereof | 成都大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12459936-B2 | Benzamide antibacterial agents | PURDUE RESEARCH FOUNDATION (US) | 2025-11-04 | — | — | US | disclosed |
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| EP-4531838-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | Kuda Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024092039-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023234970-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA Therapeutics, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391767-A1 | BENZAMIDE ANTIBACTERIAL AGENTS | PURDUE RESEARCH FOUNDATION | 2023-12-07 | — | — | US | disclosed |
| EP-2948446-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-20150275076-A1 | Non-crystallizable Pi-conjugated Molecular Glass Mixtures, Charge Transporting Molecular Glass Mixtures, Luminescent Molecular Glass Mixtures, or Combinations Thereof for Organic Light Emitting Diodes and other Organic Electronics and Photonics Applications | Molaire Consulting | 2015-10-01 | — | — | US | disclosed |
| US-20150275076-A1 | Non-crystallizable Pi-conjugated Molecular Glass Mixtures, Charge Transporting Molecular Glass Mixtures, Luminescent Molecular Glass Mixtures, or Combinations Thereof for Organic Light Emitting Diodes and other Organic Electronics and Photonics Applications | Molaire Consulting | 2015-10-01 | — | — | US | disclosed |
| CN-103980222-A | 2-amido-5-substituted-1,3,4-oxadiazole as well as preparation method and application thereof | UNIV SHAANXI SCIENCE & TECH | 2014-08-13 | — | — | CN | disclosed |
| WO-2014114532-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| US-20140179735-A1 | TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF TO MODULATE THE ACTIVITY OF ENZYMESp INVOLVED IN THE PATHOLOGY OF MYCOBACTERIUM TUBERCULOSIS | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2014-06-26 | — | — | US | disclosed |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| US-20070244071-A1 | Treatment of proliferative diseases | MOUNT SINAI HOSPITAL (CA) | 2007-10-18 | — | — | US | disclosed |
| US-20070244071-A1 | Treatment of proliferative diseases | MOUNT SINAI HOSPITAL (CA) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391767-A1 | BENZAMIDE ANTIBACTERIAL AGENTS | HDAC6, HDAC5, HDAC3 | KDM4E 1365/4885NOTUM 1685/4885DGAT1 848/4885 |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | HIF1AN, HIF1A, EGLN2 | KDM4E 1020/4885NOTUM 4855/4885DGAT1 3995/4885 |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | KDM4E 1274/4885NOTUM 1467/4885DGAT1 1098/4885 |
| US-12459936-B2 | Benzamide antibacterial agents | HDAC6, HDAC5, HDAC3 | KDM4E 1365/4885NOTUM 1685/4885DGAT1 848/4885 |
| US-20140179735-A1 | TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF TO MODULATE THE ACTIVITY OF ENZYMESp INVOLVED IN THE PATHOLOGY OF MYCOBACTERIUM TUBERCULOSIS | PPP3CB, PPP4C, PTPRB | KDM4E 739/4885NOTUM 1223/4885DGAT1 4072/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | KDM4E 1963/4885NOTUM 1463/4885DGAT1 4017/4885 |
| US-20070244071-A1 | Treatment of proliferative diseases | CCNO, CCNY, CCNI | KDM4E 2806/4885NOTUM 3210/4885DGAT1 2772/4885 |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | KDM4E 2198/4885NOTUM 3561/4885DGAT1 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.